Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.
A proposed amendment in Mexican law needs to be implemented urgently in order to adapt legislation to include provisions in accordance with the UPOV Convention, as Luz Flores of Uhthoff, Gómez Vega & Uhthoff reports.
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.
Depending on the facts and the content of the applications, an Arrow-type declaration could be made on grounds of insufficiency against divisional applications, say David Holt and Tony Proctor of Potter Clarkson.
Costa Rica has released new rules for the clinical investigation of adult stem cells, as María del Pilar López and Esteban Monge of Zürcher Lawyers report.
Patenting antibodies across different jurisdictions can be a difficult task, as Kathy Coulter, senior IP counsel at Bristol-Myers Squibb, tells LSIPR.
A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.
BIO-Europe heads to Scandinavia for the first time, as Copenhagen plays host in November. LSIPR finds out more.
The issue of inefficiencies in the life sciences IP market is a hot topic to be discussed at the Life Science IP Forum in London in November, as LSIPR finds out.
While personalised medicine is a challenging area for drug developers, there are a number of potential solutions, as LSIPR finds out.